CD274 and non-small cell lung carcinoma: Recently, the IMpower010 trial revealed that adjuvant chemotherapy followed by maintenance with atezolizumab showed the significant prolongation of disease-free survival (DFS) in patients with PD-L1 TC ≥ 1% stage II to IIIA (HR, 0.66; 95% CI, 0.50–0.88) NSCLC [14].